BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 12473970)

  • 1. Monoamine oxidase inhibitors: a new generation.
    Robinson DS
    Psychopharmacol Bull; 2002; 36(3):124-38. PubMed ID: 12473970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transdermal selegiline.
    Patkar AA; Pae CU; Zarzar M
    Drugs Today (Barc); 2007 Jun; 43(6):361-77. PubMed ID: 17612708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transdermal selegiline: the new generation of monoamine oxidase inhibitors.
    Patkar AA; Pae CU; Masand PS
    CNS Spectr; 2006 May; 11(5):363-75. PubMed ID: 16641841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial.
    Amsterdam JD; Bodkin JA
    J Clin Psychopharmacol; 2006 Dec; 26(6):579-86. PubMed ID: 17110814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selegiline transdermal system: a novel treatment option for major depressive disorder.
    Nandagopal JJ; DelBello MP
    Expert Opin Pharmacother; 2009 Jul; 10(10):1665-73. PubMed ID: 19527191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Translating the evidence on atypical depression into clinical practice.
    Hyman Rapaport M
    J Clin Psychiatry; 2007; 68 Suppl 3():31-6. PubMed ID: 17348765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The selegiline transdermal system in major depressive disorder: a systematic review of safety and tolerability.
    Robinson DS; Amsterdam JD
    J Affect Disord; 2008 Jan; 105(1-3):15-23. PubMed ID: 17568687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder.
    Amsterdam JD
    J Clin Psychiatry; 2003 Feb; 64(2):208-14. PubMed ID: 12633131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapy with monoamine oxidase inhibitors and other antidepressants or stimulants: strategies for the management of treatment-resistant depression.
    Thomas SJ; Shin M; McInnis MG; Bostwick JR
    Pharmacotherapy; 2015 Apr; 35(4):433-49. PubMed ID: 25884531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A critical appraisal of the selegiline transdermal system for major depressive disorder.
    Bied AM; Kim J; Schwartz TL
    Expert Rev Clin Pharmacol; 2015; 8(6):673-81. PubMed ID: 26427518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current place of monoamine oxidase inhibitors in the treatment of depression.
    Shulman KI; Herrmann N; Walker SE
    CNS Drugs; 2013 Oct; 27(10):789-97. PubMed ID: 23934742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selegiline transdermal system: current awareness and promise.
    Pae CU; Lim HK; Han C; Neena A; Lee C; Patkar AA
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Aug; 31(6):1153-63. PubMed ID: 17614182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of relapse in patients with major depressive disorder in a 52-week, fixed dose, double blind, randomized trial of selegiline transdermal system (STS).
    Jang S; Jung S; Pae C; Kimberly BP; Craig Nelson J; Patkar AA
    J Affect Disord; 2013 Dec; 151(3):854-9. PubMed ID: 24021959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial.
    Feiger AD; Rickels K; Rynn MA; Zimbroff DL; Robinson DS
    J Clin Psychiatry; 2006 Sep; 67(9):1354-61. PubMed ID: 17017821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MAOIs and transdermal delivery.
    Vandenberg CM
    J Clin Psychiatry; 2012 Sep; 73(9):e28. PubMed ID: 23059160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The transdermal delivery system of monoamine oxidase inhibitors.
    VanDenBerg CM
    J Clin Psychiatry; 2012; 73 Suppl 1():25-30. PubMed ID: 22951239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transdermal selegiline for the treatment of major depressive disorder.
    Lee KC; Chen JJ
    Neuropsychiatr Dis Treat; 2007; 3(5):527-37. PubMed ID: 19300583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Critical appraisal of selegiline transdermal system for major depressive disorder.
    Cristancho MA; Thase ME
    Expert Opin Drug Deliv; 2016; 13(5):659-65. PubMed ID: 26837935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selegiline transdermal system: in the treatment of major depressive disorder.
    Frampton JE; Plosker GL
    Drugs; 2007; 67(2):257-65; discussion 266-7. PubMed ID: 17284087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoamine oxidase inhibitors. A perspective on their use in the elderly.
    Volz HP; Gleiter CH
    Drugs Aging; 1998 Nov; 13(5):341-55. PubMed ID: 9829163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.